Topics in Clinical Biosecurity: Anthrax
              

Listed below are all CBN articles on Anthrax published since 2005

• 04-09-2019: The Value of a Rapid Anthrax Triage Tool with Minimal Need for Diagnostic Testing A new triage tool to identify those who have signs and symptoms consistent with anthrax is described in an article.
• 04-01-2016: A Clinical Tool for Anthrax Meningitis Screening in Mass Casualty Settings Meningitis can be a complication of anthrax infection but can be difficult to diagnose in a mass casualty setting.
• 03-06-2015: An Update on Bioterrorism-Related Conditions In the months and early years following these anthrax attacks, the US embarked on the important task of readying the nation for another biological attack
• 03-21-2014: New Anthrax Guidelines Evidence-based clinical guidance for treatment of anthrax is difficult to derive because clinical data are limited
• 05-25-2012: Additional Forensic Investigation of 2001 Anthrax Attacks FBI’s conclusion that USAMRIID scientist Dr. Ivins perpetrated the anthrax attacks of 2001 is largely built on an extensive microbial forensics investigation.
• 04-13-2012: The Effect of Anti-lethal Toxin Antibodies on Anthrax Mortality Results of a recent study suggest that treatment with antitoxin antibodies may be effective for all cases of anthrax that progress to septic shock.
• 02-17-2012: Genetic Susceptibility to Anthrax Study suggests that susceptibility to anthrax toxins may be genetic. This sheds light on the relationship between anthrax toxins and human cell receptors.
• 09-02-2011: Anthrax-like Disease Caused by Bacillus cereus Of the Bacillus species known to cause human disease, only B. anthracis is generally recognized as capable of causing fulminant disease.
• 09-17-2010: Hundreds of Cutaneous Anthrax Cases in Bangladesh More than 400 cases of cutaneous anthrax have been reported in Bangladesh. None have been fatal, and all have been linked to infected cattle.
• 01-22-2010: Anthrax Cases Among Heroin Users in Europe Illustrate Novel Risk Cases of anthrax in Scotland and Germany highlight a new risk—recreational heroin use. Only 1 prior case of anthrax infection in a heroin user has been reported
• 01-08-2010: Unusual Case of GI Anthrax in New Hampshire Raises Questions NH HHS announced that a female member of a drumming group was diagnosed with gastrointestinal anthrax, presumably contracted at an event on December 4.
• 04-14-2008: CDC Publishes Report on Meeting of Experts to Update Guidelines for Management of Anthrax On March 13-14, 2006, the CDC, in collaboration with the Southeastern Center for Emerging Biologic Threats, convened a meeting in Atlanta
• 03-14-2008: The Use of MedKits to Augment Rapid Distribution of Antibiotics after an Anthrax Attack Following an anthrax attack, many lives could be saved by timely distribution of antibiotics to exposed populations
• 09-28-2007: HHS Award Multiple Contracts for Anthrax Countermeasures Elusys Therapeutics, Inc., issued a press release announcing the award of a $12 million contract from the HHS’ BARDA/NIAID for advanced development of Anthim™.
• 09-14-2007: Symptoms of Anthrax in Children May be More Varied than Previously Thought A review of data suggests that the clinical presentation of anthrax among pediatric patients may be more varied that previously recognized.
• 01-26-2007: Partial Anthrax Vaccination Stimulates Significant Antibody Response Report on their study of serum anti-protective antigen (PA) concentrations in marines who had been previously vaccinated with the FDA-licensed AVA.
• 01-18-2007: Immunological Responses after Exposure to Anthrax Spores in the U.S. Capitol, 2001 Doolan and colleagues analyze the humoral and cell-mediated immune responses to B. anthracis among persons exposed and possibly exposed to spores.
• 07-20-2006: New Anthrax Countermeasure to be Acquired by HHS HHS announced a plan to purchase 20K treatment courses of ABthrax™ at a price of $165 MM with delivery to the Strategic National Stockpile set to begin in 2009.
• 06-16-2006: Safety and Immunogenicity of the Second Generation Anthrax Vaccine Candidate Vaxgen, Inc. reported the results of a phase 1 clinical trial designed to assess the safety and immunogenicity of their recombinant anthrax vaccine candidate.
• 03-17-2006: Could the Duration of Postexposure Antibiotic Prophylaxis Against Inhalational Anthrax be Shortened? The CDC recommends 60 days of postexposure antibiotic prophylaxis in unvaccinated persons after exposure to anthrax spores.
• 02-22-2006: Isolated Case of Naturally-Occurring Inhalational Anthrax in a New York City Resident The NYC DOHMH released an alert today regarding a single case of inhalational anthrax in a 44 year old man who makes drums from unprocessed animal hides.
• 07-11-2005: Potential Anthrax Therapeutic A study published reports on a Phase I trial of a fully human monoclonal antibody against the Bacillus anthracis protective antigen.
• 06-06-2005: Disease Reporting Rules; Anthrax Anti-toxin This article focuses on two topics; the WHO issuing new rules on disease reporting, and promising results reported with new anthrax anti-toxin.
• 05-09-2005: Anthrax Meningitis While known to carry a very high mortality rate, meningitis has long been considered an infrequent manifestation of infection with Bacillus anthracis.
• 04-26-2005: Anthrax Response; New Vaccines If a large scale aerosol attack with anthrax occurs over a large city, what would be the most effective response strategy?